SPARC.NS - Sun Pharma Advanced Research Company Limited

NSE - NSE Real Time Price. Currency in INR

Sun Pharma Advanced Research Company Limited

17-B, Mahal Industrial Estate
Off Mahakali Caves Road Andheri (East)
Mumbai 400093
91 22 6645 5645

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Anilkumar RaghavanChief Exec. OfficerN/AN/A1969
Mr. Chetan M. RajparaChief Financial Officer15.14MN/AN/A
Mr. Siu-Long YaoExec. VP Clinical Devel. & OperationsN/AN/AN/A
Mr. Jaydeep IssraniSr. Gen. Mang. of Bus. Devel., Corp. Communication & Investor RelationsN/AN/AN/A
Mr. Dinesh Poosraj LahotiCompany Sec. & Compliance OfficerN/AN/AN/A
Dr. Rajesh RanganathanVice-Pres Corp. Devel.N/AN/AN/A
Ms. Shanta GuptaChief Human Resource OfficerN/AN/AN/A
Dr. Nitin K. Damle Ph.D.Sr. VP & Chief Innovation OfficerN/AN/AN/A
Mr. Vikram RamanathanVP & Head of Translational Devel.N/AN/AN/A
Dr. Venkata PalleExec. VP & Global Head of Drug Discovery and Preclinical Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.


Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet to develop an S1P receptor 1 agonist for autoimmune disorders. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited.

Corporate Governance

Sun Pharma Advanced Research Company Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.